Obstetrics and gynecology
-
Obstetrics and gynecology · Jun 2020
Randomized Controlled Trial Multicenter StudyElagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas. ⋯ AbbVie Inc funded this study.